From HIV to Alzheimer's, immunoassays are key in modern diagnostics. Explore how innovative advancements are driving this essential technology forward to improve clinical outcomes worldwide. https://bit.ly/4dSj9gk #HighSensitivityDiagnostics #ImmunoassayTesting #Diagnostics
Beckman Coulter Diagnostics
Medical Equipment Manufacturing
Brea, California 332,500 followers
Applying the power of science and technology to Relentlessly Reimagine Healthcare, One Diagnosis at a Time
About us
A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., Beckman Coulter Diagnostics has more than 11,000 global team members. Beckman Coulter is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health.
- Website
-
https://www.beckmancoulter.com
External link for Beckman Coulter Diagnostics
- Industry
- Medical Equipment Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Brea, California
- Type
- Public Company
- Founded
- 1935
- Specialties
- Laboratory Systems, CE, Lab Automation, Immunoassay, Hematology, Information Systems, Integrated Systems, Diagnostics, Chemistry, Microbiology, Clinical Informatics, Lab 2.0, Urinalysis, Automation, Clinical Chemistry, In-vitro Diagnostics, Sepsis Diagnosis and Management, Medical Devices, Analyzers, and Core Laboratory
Locations
-
Primary
Get directions
250 S Kraemer Blvd
Brea, California 92821, US
Employees at Beckman Coulter Diagnostics
Updates
-
Zivjena Vucetic, MD, PhD, Chief Medical Officer at Beckman Coulter Diagnostics commented on this exciting news: “The opportunity to partner with the Davos Alzheimer's Collaborative enables our work at Beckman Coulter Diagnostics to develop a scalable, patient friendly blood-based test for Alzheimer’s disease. DAC’s access to a wide range of Alzheimer’s disease patient cohorts, especially from under-represented populations, highlights the true heterogeneity of the disease. Accessing diverse patient samples is critical to our ability to develop a high-quality, reliable immunoassay test available to patients around the world.” https://bit.ly/4iFvR5D #diagnostics #beckmancoulter #alzheimers
Breaking: The Davos Alzheimer’s Collaborative is proud to announce our collaboration with Janssen Research & Development and Beckman Coulter Diagnostics to advance the assay validation of blood-based biomarkers (BBMs) for Alzheimer’s disease for global use in diverse populations. DAC's Global Cohorts Program has enabled this transnational, multi-party collaboration and supported biosample collection at The Catholic University of Korea in South Korea in a study led by Hyun Kook Lim, MD PhD. The samples will represent people across all stages of #Alzheimers disease—healthy control, mild cognitive impairment, pre-clinical Alzheimer’s disease, and Alzheimer’s disease—based on clinical assessments and amyloid PET confirmation. DAC’s efforts to build an ecosystem of industry partners are meant to bridge knowledge gaps of low and middle-income country populations and enable the development of globally generalizable blood-based tests for Alzheimer’s disease. This inclusive research program is critical to DAC’s work to diversify research since nearly all BBM studies in Alzheimer’s disease to date have been conducted on Caucasian populations of Western European or American origin. Learn more here: https://lnkd.in/eifEQbc2 Jaishree Singh, MSPH (she/her), Irene Meier, Vaibhav Narayan, Drew Holzapfel, Caroline Hubbard, Connor McLaughlin, George Vradenburg, Susan Oliver
-
Accurate measurement of Anti-Müllerian Hormone (AMH) levels is important to understanding ovarian reserve. With observed Limit of Quantitation (LoQ) estimates of 0.001 to 0.003 ng/mL (0.01 to 0.02 pmol/L), the Access AMH test on the DxI 9000 Immunoassay Analyzer is up to 20 times more sensitive than AMH assays on competitive analyzers. 💡 Learn how extremely low AMH measurements provide value of clinical significance: https://bit.ly/4gP4tBk
-
-
Emerging blood tests for Alzheimer's disease, like p-Tau 217, plasma amyloid beta, and neurofilament light chain, promise a new era in Alzheimer’s disease diagnostics. Labs will likely play a crucial role in early detection. Are you ready? Learn more from Arindam Ghosh, MD, PhD about the biomarkers and promising blood-based tests involved in for Alzheimer's and other neurodegenerative diseases in the latest edition of @CLPmag. https://bit.ly/3ZQwFx8 #BloodBasedBiomarkers #NeurodegenerativeDisease #AlzheimersDisease
-
-
Beckman Coulter Diagnostics reposted this
See how Kevin O’Reilly is advocating for #innovation and #sustainability in #diagnostics at Beckman Coulter Diagnostics in our #ReadoftheWeek 📚👇 https://ow.ly/iSGu50U0cEj
-
-
Early identification and individualized treatment for sepsis are crucial. Explore how novel Dx tools are making a difference in the fight against this deadly syndrome. Read this article in #BeckerHealthcare to learn about new tools for the diagnosis and management of sepsis. #HostResponsetoInfection #EmergencyMedicine #Diagnostics
-
-
Meet David Schumm, manager of manufacturing science. Learn how he has achieved his potential at Beckman Coulter and is committed to helping others grow their careers. #AccelerateYourPotential #LifeAtBecDx Visit our site to learn more. https://bit.ly/3ZdzrwG
-
Assays for blood-based biomarkers are non-invasive and easier to administer, potentially revolutionizing #AlzheimersDisease diagnosis. Learn more about their advantages from experts at #CTAD2024. Read blog >> https://bit.ly/3ZmKi5C
-
-
Discover the outstanding precision and sensitivity of Beckman Coulter's DxI 9000 immunoassay analyzer on a sample cohort studying RUO p-Tau217 in blood samples and how it correlates with amyloid pathology. A promising step toward advancing Alzheimer’s disease research. Read the study: https://bit.ly/4ekWrOV
-
-
Beckman Coulter Diagnostics reposted this
Join us on Dec 17 for an exclusive roundtable discussion featuring leading experts in high-sensitivity immunoassay, to discuss its role in clinical practice. During this live event with Sten Westgard, WESTGARD QC, Dr. Frank Peacock, Baylor College of Medicine and Tracy Mangunlay, Adventist Health, we’ll explore key topics, from troponin testing to insights on management, implementation, and regulatory perspectives. Register here: https://lnkd.in/ePp_i5SG #CLINICAL24 #Immunoassay #CardiacCare #Troponin Beckman Coulter Diagnostics
-